Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Management
Scientific Advisory Board
Corporate Governance
Investors
Investor Welcome
Company Fact Sheet
ASX Announcements
Neuroprotection Program
Cardioprotection Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
>
Cardioprotection Program
Investor Welcome
Company Fact Sheet
ASX Announcements
Neuroprotection Program
Cardioprotection Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
Cardioprotection Program
Filter by Year:
2024
2023
2022
2021
2020
10-Oct-2022
Efficacy Study Published in Journal of Lipid Research
20-Jul-2022
Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis
29-Jun-2022
Cholesterol-Lowering Program Update
17-May-2022
European Patent to be Granted for Cholesterol-Lowering Drug
1
